Treatment

Phase II/III GAIN trial results: atuzaginstat for disease modification in Alzheimer’s disease

Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease

The potential of lecanemab for the treatment of early Alzheimer’s disease

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Lecanemab: Phase II open-label extension results

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer’s Disease

Highlights from AAIC: Targeting the immune response to treat AD

AAIC 2021 highlights in the vascular space

Developing gingipain inhibitors for the treatment of Alzheimer’s disease

COR388: a novel approach to treating Alzheimer’s based on the gingipain hypothesis

Targeting P. gingivalis infection to treat Alzheimer’s: the evidence

Phase II/III GAIN trial of a novel lysine-gingipain inhibitor for the treatment of Alzheimer’s